肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

FLT3调节抗原作为白血病反应性细胞毒性T淋巴细胞的靶标

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

原文发布日期:2011-03-18

DOI: 10.1038/bcj.2011.12

类型: Original Article

开放获取: 是

英文摘要:

摘要翻译: 

原文链接:

文章:

FLT3调节抗原作为白血病反应性细胞毒性T淋巴细胞的靶标

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

原文发布日期:2011-03-18

DOI: 10.1038/bcj.2011.12

类型: Original Article

开放获取: 是

 

英文摘要:

The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute myeloid leukemia (AML). Internal tandem duplications (ITD) of the juxtamembrane domain lead to the constitutive activation of the FLT3 kinase inducing the activation of multiple genes, which may result in the expression of leukemia-associated antigens (LAAs). We analyzed the regulation of LAA in FLT3-wild-type (WT)- and FLT3-ITD+ myeloid cells to identify potential targets for antigen-specific immunotherapy for AML patients. Antigens, such as PR-3, RHAMM, Survivin, WT-1 and PRAME, were upregulated by constitutively active FLT3-ITD as well as FLT3-WT activated by FLT3 ligand (FL). Cytotoxic T-cell (CTL) clones against PR-3, RHAMM, Survivin and an AML-directed CTL clone recognized AML cell lines and primary AML blasts expressing FLT3-ITD, as well as FLT3-WT+ myeloid dendritic cells in the presence of FL. Downregulation of FLT3 led to the abolishment of CTL recognition. Comparing our findings concerning LAA upregulation by the FLT3 kinase with those already made for the Bcr-Abl kinase, we found analogies in the LAA expression pattern. Antigens upregulated by both FLT3 and Bcr-Abl may be promising targets for the development of immunotherapeutical approaches against myeloid leukemia of different origin.

 

摘要翻译: 

FMS样酪氨酸激酶3(FLT3)在急性髓系白血病(AML)中高表达。近膜结构域的内部串联重复(ITD)导致FLT3激酶构成性激活,进而诱导多个基因的活化,这可能引发白血病相关抗原(LAAs)的表达。我们分析了FLT3野生型(WT)和FLT3-ITD+髓系细胞中LAA的调控机制,以确定AML患者抗原特异性免疫治疗的潜在靶点。组成性激活的FLT3-ITD以及经FLT3配体(FL)激活的FLT3-WT均能上调PR-3、RHAMM、Survivin、WT-1和PRAME等抗原的表达。针对PR-3、RHAMM、Survivin的细胞毒性T细胞(CTL)克隆及一个AML定向CTL克隆,能够识别表达FLT3-ITD的AML细胞系和原代AML原始细胞,以及在FL存在下的FLT3-WT+髓系树突状细胞。下调FLT3表达则消除了CTL的识别能力。通过比较FLT3激酶与已研究的Bcr-Abl激酶对LAA的上调作用,我们发现两者在LAA表达模式上存在相似性。受FLT3和Bcr-Abl共同上调的抗原可能成为针对不同来源髓系白血病开发免疫治疗方法的有前景靶点。

 

原文链接:

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……